The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Subscribe To Our Newsletter & Stay Updated
